5-Hydroxytryptamine and human small intestinal motility: effect of inhibiting 5-hydroxytryptamine reuptake
- PMID: 8174987
- PMCID: PMC1374798
- DOI: 10.1136/gut.35.4.496
5-Hydroxytryptamine and human small intestinal motility: effect of inhibiting 5-hydroxytryptamine reuptake
Abstract
Parenteral 5-hydroxytryptamine stimulates small intestinal motility, but the effect of continuous stimulation with 5-hydroxytryptamine on the human migrating motor complex is unknown. Using a selective 5-hydroxytryptamine reuptake inhibitor, paroxetine, this study investigated the effect of indirect 5-hydroxytryptamine agonism on fasting small intestinal motility and transit. Eight healthy subjects were studied while receiving paroxetine 30 mg daily for five days and while receiving no treatment, in random order. Ambulant small intestinal motility was recorded from five sensors positioned from the duodenojejunal flexure to the ileum for 16-18 hours. Paroxetine reduced the migrating motor complex periodicity mean (SEM) from 81 (6) min to 67 (4) min (p < 0.05), and increased the propagation velocity of phase III from 3.1 to 4.7 cm/min in the proximal jejunum (p < 0.01), and from 1.6 to 3.4 cm/min distally (p < 0.001). Orocaecal transit time measured by lactulose hydrogen breath test was reduced by paroxetine from 70 (9) min to 48 (7) min (p < 0.05). These data suggest that 5-hydroxytryptamine participates in the control of migrating motor complexes in humans, and that selective 5-hydroxytryptamine reuptake inhibitors have a prokinetic action in the human small intestine.
Similar articles
-
Ambulatory small intestinal motility in 'diarrhoea' predominant irritable bowel syndrome.Gut. 1994 Feb;35(2):203-10. doi: 10.1136/gut.35.2.203. Gut. 1994. PMID: 8307470 Free PMC article.
-
Role of fasting gastrointestinal motility in the variability of gastrointestinal transit time assessed by hydrogen breath test.Gut. 1991 Oct;32(10):1127-30. doi: 10.1136/gut.32.10.1127. Gut. 1991. PMID: 1955166 Free PMC article.
-
Effect of a tricyclic antidepressant on small intestinal motility in health and diarrhea-predominant irritable bowel syndrome.Dig Dis Sci. 1995 Jan;40(1):86-95. doi: 10.1007/BF02063948. Dig Dis Sci. 1995. PMID: 7821126 Clinical Trial.
-
Intestinal motor function in irritable bowel syndrome.Dig Dis. 1994 Mar-Apr;12(2):72-84. doi: 10.1159/000171440. Dig Dis. 1994. PMID: 8045030 Review.
-
Neurohormonal control of intestinal transit.Reprod Nutr Dev. 1994;34(6):513-25. doi: 10.1051/rnd:19940601. Reprod Nutr Dev. 1994. PMID: 7840868 Review.
Cited by
-
Clinical and Translational Considerations for Understanding Depression and Anxiety in Patients with Inflammatory Bowel Disease.Gastroenterol Res Pract. 2021 Mar 5;2021:6689443. doi: 10.1155/2021/6689443. eCollection 2021. Gastroenterol Res Pract. 2021. PMID: 33747075 Free PMC article. Review.
-
Treatment of Functional GI Disorders With Psychotropic Medicines: A Review of Evidence With a Practical Approach.Gastroenterol Hepatol (N Y). 2006 Sep;2(9):678-688. Gastroenterol Hepatol (N Y). 2006. PMID: 28316538 Free PMC article.
-
Drug development for the irritable bowel syndrome: current challenges and future perspectives.Front Pharmacol. 2013 Feb 1;4:7. doi: 10.3389/fphar.2013.00007. eCollection 2013. Front Pharmacol. 2013. PMID: 23378837 Free PMC article.
-
Serotonergic modulation of visceral sensation: lower gut.Gut. 2002 Jul;51 Suppl 1(Suppl 1):i81-6. doi: 10.1136/gut.51.suppl_1.i81. Gut. 2002. PMID: 12077074 Free PMC article. Review.
-
Serotonin pharmacology in the gastrointestinal tract: a review.Naunyn Schmiedebergs Arch Pharmacol. 2008 May;377(3):181-203. doi: 10.1007/s00210-008-0276-9. Epub 2008 Apr 9. Naunyn Schmiedebergs Arch Pharmacol. 2008. PMID: 18398601 Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources